New PET scan could predict who benefits from targeted lung cancer therapy
NCT ID NCT07685197
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard and one experimental—to see which better tracks how well the drug is working. The goal is to find a more accurate way to measure treatment response and improve outcomes for patients with limited options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan
- What this could lead to
- If successful, this could identify a better imaging method to predict which patients benefit from TROP2-targeted therapy, potentially improving treatment decisions for hard-to-treat lung cancer.
- What could go wrong
- This is a Phase 2 study with only 100 participants, so results may not apply broadly. The drug can cause side effects like nausea, fatigue, and low blood cell counts, and the imaging technique is experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR ACTIVATING MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
- New drug combo aims to shrink tough lung tumors
- New drug combo aims to outsmart lung cancer that resists immunotherapy
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation